INTELLIGENT BIO SOLUTIONS INC. (INBS): Nasdaq/NYSE listing notice — Nasdaq deficiency letter for bid price non-compliance; 1-for-10 reverse stock split effected

INTELLIGENT BIO SOLUTIONS INC.

Received Nasdaq deficiency letter on Dec 15 for closing bid price below $1 for 30 consecutive business days.
Initial compliance period runs through June 15, 2026; cure if bid price ≥ $1 for 10 consecutive days.
Filed and effected a 1-for-10 reverse stock split on Dec 15; split-adjusted trading began Dec 16.
If non-compliant by June 15, may qualify for an additional 180-day period if meeting other listing standards.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

INTELLIGENT BIO SOLUTIONS INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

December 15, 2025, Intelligent Bio Solutions Inc. (the “Company”) received a deficiency letter from the Nasdaq Listing Qualifications Department (the “Staff”) notifying the Company that because the closing bid price for the Company’s common stock was below $1.00 per share for the last 30 consecutive business days, the Company did not meet the $1.00 per share minimum bid price requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). The deficiency letter does not result in the immediate delisting of the Company’s common

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

INTELLIGENT BIO SOLUTIONS INC. filing history →

Source: SEC EDGAR

accession 0001493152-25-028003

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.